Paula Alves, CEO of iBET, participated in a panel on the National Television show “Expresso da Meia-Noite” (SIC Notícias).
In its participation, Paula Alves highlights the importance of investment in Research and Development activities and in cutting-edge technologies to support the development of innovative medicines and biopharmaceuticals.
Additionally, Paula Alves stressed that there is an increasing need to attract talent and prepare the next generations of scientists, technologists and engineers to create more qualified jobs in the development of innovative products.
Click the image below to see the full episode.
• Public-private partnerships are very important mechanisms to ensure a continuous and regular investment in Research & Development. This continuous investment is crucial when working with innovative medicines and biopharmaceuticals.
• Research in innovative medicines requires a very complex system, multidisciplinary teams and close collaboration between different players. Collaboration and multidisciplinary are key to advance scientific knowledge.
• Only orchestrated collaborations between fundamental and applied research enables transferring major innovation from early research setups into industry. As an example, Genibet produced the mRNA batches for Moderna, an essential scale-up process to move from the fundamental concept to application and distribution.